The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

Journal of Allergy and Clinical Immunology

Volumn 115, Issue 3, 2005, Pages 459-465

  Holgate, Stephen ^a   Casale, Thomas ^b   Wenzel, Sally ^c   Bousquet, Jean ^d   Deniz, Yamo ^e   Reisner, Colin ^f  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b CREIGHTON UNIVERSITY   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

^e GENENTECH INC   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allergic inflammation; Anti inflammatory; B cell; Fc RI; Fc RII; IgE; Omalizumab; T cell

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; METHACHOLINE; OMALIZUMAB;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIGEN FUNCTION; B LYMPHOCYTE; BASOPHIL; BRONCHUS HYPERREACTIVITY; CELL ACTIVATION; CLINICAL TRIAL; DENDRITIC CELL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; EOSINOPHIL; EOSINOPHILIA; HOUSE DUST ALLERGY; HUMAN; INFLAMMATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAST CELL; PRIORITY JOURNAL; RAGWEED; REVIEW; T LYMPHOCYTE; TH2 CELL;

EID: 14844300188     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2004.11.053     Document Type: Review

References (38)

1. B. Burrows, F.D. Martinez, M. Halonen, R.A. Barbee, and M.G. Cline Association of asthma with serum IgE levels and skin-test reactivity to allergens N Engl J Med 320 1989 271 277
2. A.B. Kay Allergy and allergic diseases N Engl J Med 344 2001 109 113
3. P.G. Holt, C. Macaubas, P.A. Stumbles, and P.D. Sly The role of allergy in the development of asthma Nature 402 suppl 1999 B12 B17
4. European Network for Understanding Mechanisms of Severe Asthma (ENFUMOSA) The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma Eur Respir J 22 2003 470 477
5. L. Fregonese, A. Patel, A. van Schadewijk, M.A. Santos, M. Dolhnikoff, and P.J. Sterk Expression of the high-affinity IgE receptor (FcεRI) is increased in fatal asthma [abstract] Am J Respir Crit Care Med 169 2004 A297
6. K. Sayama, M. Diehn, K. Matsuda, C. Lunderius, M. Tsai, and S.Y. Tam Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-11 BMC Immunol 3 2002 5
7. T. Kawakami, and S.J. Galli Regulation of mast-cell and basophil function and survival by IgE Nat Rev Immunol 2 2002 773 786
8. D. MacGlashan Jr., L.M. Lichtenstein, J. McKenzie-White, K. Chichester, A.J. Henry, and B.J. Sutton Upregulation of FcepsilonRI on human basophils by IgE antibody is mediated by interaction of IgE with FcepsilonRI J Allergy Clin Immunol 104 1999 492 498
9. D.W. MacGlashan Jr., B.S. Bochner, D.C. Adelman, P.M. Jardieu, A. Togias, and L.M. Lichtenstein Serum IgE level drives basophil and mast cell IgE receptor display Int Arch Allergy Immunol 113 1997 45 47
10. C.M. Williams, and S.J. Galli The diverse potential effector and immunoregulatory roles of mast cells in allergic disease J Allergy Clin Immunol 105 2000 847 859
11. J. Kitaura, J. Song, M. Tsai, K. Asai, M. Maeda-Yamamoto, and A. Mocsai Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI Proc Natl Acad Sci U S A 100 2003 12911 12916
12. B. Foster, D.D. Metcalfe, and C. Prussin Human dendritic cell 1 and dendritic cell 2 subsets express FcεRI: correlation with serum IgE and allergic asthma J Allergy Clin Immunol 112 2003 1132 1138
13. D.W. MacGlashan Jr., B.S. Bochner, D.C. Adelman, P.M. Jardieu, A. Togias, and J. McKenzie-White Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody J Immunol 158 1997 1438 1445
14. H. Lin, K.M. Boesel, D.T. Griffith, C. Prussin, B. Foster, and F.A. Romero Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils J Allergy Clin Immunol 113 2004 297 302
15. E. Ädelroth, S. Rak, T. Haahtela, G. Aasand, L. Rosenhall, and O. Zetterstrom Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis J Allergy Clin Immunol 106 2000 253 259
16. T.B. Casale, J. Condemi, C. LaForce, A. Nayak, M. Rowe, and M. Watrous Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial JAMA 286 2001 2956 2967
17. C. Prussin, D.T. Griffith, K.M. Boesel, H. Lin, B. Foster, and T.B. Casale Omalizumab treatment downregulates dendritic cell FcεRI expression J Allergy Clin Immunol 112 2003 1147 1154
18. Hayek B, Heil PM, Laimer M, Maurer D, Hultsch T, Stingl G. Omalizumab-induced downregulation of IgE/FcεRI on dendritic cells in patients with atopic dermatitis. Abstract presented at: XXIII EAACI Congress; June 12-16, 2004; Amsterdam, The Netherlands. 2004;224:744.
19. J.V. Fahy, H.E. Fleming, H.H. Wong, J.T. Liu, J.Q. Su, and J. Reimann The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects Am J Respir Crit Care Med 155 1997 1828 1834
20. R. Djukanović, S.J. Wilson, M. Kraft, N.N. Jarjour, M. Steel, and K.F. Chung The effects of anti-IgE (omalizumab) treatment on airways inflammation in allergic asthma Am J Respir Crit Care Med 170 2004 583 593
21. D.Y. Leung, R.J. Martin, S.J. Szefler, E.R. Sher, S. Ying, and A.B. Kay Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma J Exp Med 181 1995 33 40
22. L.P. Boulet, K.R. Chapman, J. Côté, S. Kalra, R. Bhagat, and V.A. Swystun Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response Am J Respir Crit Care Med 155 1997 1835 1840
23. O. Noga, G. Hanf, and G. Kunkel Immunological and clinical changes in allergic asthmatics following treatment with omalizumab Int Arch Allergy Immunol 131 2003 46 52
24. G.P. Currie, C.M. Jackson, D.K. Lee, and B.J. Lipworth Allergen sensitization and bronchial hyper-responsiveness to adenosine monophosphate in asthmatic patients Clin Exp Allergy 33 2003 1405 1408
25. H. Plewako, M. Arvidsson, K. Petruson, I. Oancea, K. Holmberg, and E. Adelroth The effect of omalizumab on nasal allergic inflammation J Allergy Clin Immunol 110 2002 68 71
26. T. Feuchtinger, H. Bartz, A. von Berg, F. Riedinger, J. Brauburger, and S. Stenglein Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season J Allergy Clin Immunol 111 2003 428 430
27. Ong Y, Menzies-Gow A, Matthews J, Kay AB. A randomised double-blind, placebo-controlled study to assess the effects of omalizumab (humanised monoclonal anti-IgE antibody) on the early- and late-phase skin reactions and cellular infiltrate after multiple intradermal allergen challenges. Abstract presented at: XXIII EAACI Congress; June 12-16, 2004; Amsterdam, The Netherlands. 2004;96:305.
28. L.A. Beck, G.V. Marcotte, D. MacGlashan, A. Togias, and S. Saini Omalizumab-induced reductions in mast cell FcεRI expression and function J Allergy Clin Immunol 114 2004 527 530
29. P. Chervinsky, T. Casale, R. Townley, I. Tripathy, S. Hedgecock, and A. Fowler-Taylor Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis Ann Allergy Asthma Immunol 91 2003 160 167
30. A.M. Vignola, M. Humbert, J. Bousquet, L.P. Boulet, S. Hedgecock, and M. Blogg Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR Allergy 59 2004 709 717
31. H. Milgrom, W. Berger, A. Nayak, N. Gupta, S. Pollard, and M. McAlary Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab) Pediatrics 108 2001 E36
32. W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, and G. Della-Cioppa Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
33. M. Solér, J. Matz, R. Townley, R. Buhl, J. O'Brien, and H. Fox The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics [published erratum appears in Eur Respir J 2001;18:739-40] Eur Respir J 18 2001 254 261
34. S.T. Holgate, A.G. Chuchalin, J. Hebert, J. Lotvall, G.B. Persson, and K.F. Chung Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638
35. J.G. Ayres, B. Higgins, E.R. Chilvers, G. Ayre, M. Blogg, and H. Fox Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma Allergy 59 2004 701 708
36. S. Holgate, J. Bousquet, S. Wenzel, H. Fox, J. Liu, and J. Castellsague Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality Curr Med Res Opin 17 2001 233 240
37. J. Corren, T. Casale, Y. Deniz, and M. Ashby Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma J Allergy Clin Immunol 111 2003 87 90
38. J. Bousquet, S. Wenzel, S. Holgate, W. Lumry, P. Freeman, and H. Fox Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma Chest 125 2004 1378 1386